INSMED INC

Insmed’s 33% stock surge follows a 55% revenue jump and a raised Brinsupri outlook, signaling a path to profitability and strong investor confidence.

Insmed’s analyst‑raised price targets signal growing optimism about its rare‑disease pipeline and strong market positioning, offering potential upside for long‑term investors.

Insmed’s Brinsupri earns EU approval as the first‑in‑class therapy for non‑cystic fibrosis bronchiectasis, opening a new market and boosting investor interest.

Insmed Inc. is poised for a potential uptick as it prepares to present Phase 3 ASPEN trial data for its BRINSUPRI therapy, which could secure a first-to-market position in a niche patient population and unlock substantial revenue potential.

Insmed Inc.’s stock price surged to a new 52-week high after analyst upgrades and the FDA approval of its treatment for non-cystic fibrosis bronchiectasis, BRINSUPRI.

Insmed Inc has announced positive results from its Phase 2b study for Pulmonary Arterial Hypertension, marking a significant breakthrough in rare disease treatment and boosting investor confidence in the biopharmaceutical sector.

Insmed Inc, a biopharmaceutical company, has seen a significant surge in its stock price following promising trial results for its pulmonary arterial hypertension treatment, positioning it as a leader in the biotech sector.

Insmed Inc, a biopharmaceutical company, has seen a significant surge in its stock price following promising trial results for its pulmonary arterial hypertension treatment, positioning it as a leader in the biotech sector.

Insmed Inc.’s stock surges after a Phase 2b study of its Treprostinil Palmitil Inhalation Powder shows positive results in treating Pulmonary Arterial Hypertension.

Insmed Inc. reported strong Q1 2025 financial results, with $92.8 million in revenue, a 23% increase from the same period in 2024, driven by growth in its flagship product ARIKAYCE.